Related Experiment Video
Updated: Jan 14, 2026
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.8K
Systemic chemotherapy in metastatic TNBC polarizes effector T cell differentiation
Hye-Yeon Ju1, Hyundong Yoon2, Seungpil Jung3
1Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, 22014, the Republic of Korea.
Cancer Cell International
|October 22, 2025
Summary
This study reveals key effector T cell genes in East Asian patients with metastatic triple-negative breast cancer (mTNBC). These findings offer potential new diagnostic and therapeutic targets for improving mTNBC outcomes.
Area of Science:
- Immunology
- Oncology
- Genomics
Background:
- Triple-negative breast cancer (TNBC) presents a poor prognosis with high recurrence and metastasis rates.
- Effective immunotherapy for metastatic TNBC (mTNBC) is limited by unknown resistance mechanisms.
Purpose of the Study:
- To investigate the immune landscape dynamics in East Asian patients with mTNBC.
- To identify potential diagnostic and therapeutic targets for mTNBC.
Main Methods:
- Single-cell RNA sequencing (scRNA-seq) was employed to analyze immune cells from mTNBC patients and healthy donors.
- Integration of internal and public scRNA-seq datasets comprising over 112,000 cells.
Main Results:
- Nine overexpressed genes in effector T cells (e.g., CTSW, PRF1, GZMA) were associated with favorable survival prognoses in mTNBC patients.
- Effector T cells in mTNBC patients showed increased differentiation compared to healthy donors.
Conclusions:
- This research identifies potential diagnostic and therapeutic targets within effector T cells for East Asian mTNBC.
- The study provides novel insights into the immune profile of chemotherapy-treated mTNBC.
Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:17The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K